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Abstract 
Background 
Aortic stenosis requires timely treatment with either surgical aortic valve replacement 
(SAVR) or transcatheter aortic valve replacement (TAVR). This study aimed to investigate 
the indirect impact of COVID-19 on national SAVR and TAVR activity and outcomes. 
Methods 
The UK TAVR Registry and the National Adult Cardiac Surgery Audit were used to identify 
all TAVR and SAVR procedures in England, between January 2017 and June 2020. The 
number of isolated AVR, AVR+coronary artery bypass graft (CABG) surgery, AVR+other 
surgery and TAVR procedures per month was calculated. Separate negative binomial 
regression models were fit to monthly procedural counts, with functions of time as covariates, 
to estimate the expected change in activity during COVID-19. 
Results 
We included 13376 TAVR cases, 12328 isolated AVR cases, 7829 AVR+CABG cases, and 
6014 AVR+Other cases. Prior to March 2020 (UK lockdown), monthly TAVR activity was 
rising, with a slight decrease in SAVR activity during 2019. We observed a rapid and 
significant drop in TAVR and SAVR activity during the COVID-19 pandemic, especially for 
elective cases. Cumulatively, over the period March to June 2020, we estimated an expected 
2294 (95% CI 1872, 2716) cases of severe aortic stenosis who have not received treatment. 
Conclusion 
This study has demonstrated a significant decrease in TAVR and SAVR activity in England 
following the COVID-19 outbreak. This situation should be monitored closely, to ensure that 
monthly activity rapidly returns to expected levels. There is potential for significant backlog 
in the near-to-medium term, and potential for increased mortality in this population. 
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Introduction 
The pandemic of the novel coronavirus disease 2019 (COVID-19) [1] presents a global health 
crisis and has resulted in significant excess mortality worldwide [2]. As a result, many 
countries have imposed restrictions based on physical/social distancing and on movement 
(i.e. ‘lockdowns’), with the aim of mitigating and managing the spread of COVID-19. In the 
UK, the first confirmed case was recorded on 28th January 2020, with the first fatality from 
COVID-19 being announced on 5th March 2020 [3]. A UK-wide lockdown was initiated on 
23rd March 2020. 
The lockdown restrictions, and the pandemic itself, have resulted in widespread changes in 
operational activity of health services. Many countries and healthcare systems have faced 
significant pressure on services, particularly within critical care [4,5]. This has necessitated 
the need for restructuring of resources to meet those needs. Simultaneously, COVID-19 has 
influenced the ways in which people interact with health services. For example, previous 
studies have illustrated that there have been significant decreases in the number of admissions 
and diagnosis of many health conditions, including for acute coronary syndromes [6–10], 
stroke [11,12] and cancer referrals [13]. It is crucial to understand the consequences of this on 
public health and on future healthcare resource requirements, especially for conditions 
requiring timely healthcare interventions due to their adverse effect on prognosis, such as 
severe symtomatic aortic stenosis. 
Aortic stenosis is the most common valvular heart disease and, while many patients with 
aortic stenosis are asymptomatic, the onset of symptoms is associated with rapid 
deterioration. Thus, timely treatment by either surgical aortic valve replacement (SAVR) or 
transcatheter aortic valve replacement (TAVR) is key. SAVR has been the default treatment 
strategy for symptomatic aortic stenosis, although TAVR has emerged as an effective option 
across operative-risk strata [14–18]. While the activity and outcomes for aortic valve 
replacements (surgical and transcatheter) have been studied in historic cohorts [19], there is a 
lack of data in contemporary practice, especially surrounding the impact of COVID-19 from 
a national perspective. 
Therefore, the aim of this study was to investigate the activity and post-procedural outcomes 
of all aortic valve replacements (AVRs) in contemporary practice, from a national 
perspective, and to investigate the indirect impact of COVID-19 on activity and outcomes. 
The intention is to estimate the effect of reduced activity on projected backlog of cases. 
Methods 
UK TAVR Registry 
The UK TAVR registry collects patient demographics, risk factors for intervention, 
procedural details, and in-hospital adverse outcomes/complications for every TAVR 
procedure undertaken within the UK [20]. Data collection occurs prospectively at each 
contributing centre, and is submitted to the National Institute for Cardiovascular Outcomes 
Research (NICOR). Data collection is mandated for all centres licensed to undertake TAVR 
procedures. We extracted data from NICOR on all TAVR procedures undertaken in England 
between January 2017, and June 2020. 
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UK National Adult Cardiac Surgery Audit 
The NICOR National Adult Cardiac Surgery Audit (NACSA) contains data on all major heart 
operations undertaken in the UK and Ireland [21]. We extracted all surgical aortic valve 
replacements (SAVRs) undertaken in England between 2017 and 2020. We defined SAVR to 
be any procedure that was recorded in NASCA as being a valve replacement procedure, and 
where the aortic valve implant type was recorded as being mechanical, biological, homograft 
or autograft replacement. Moreover, we further categorised SAVRs into (i) isolated AVR, (ii) 
AVR with coronary artery bypass graft (AVR+CABG), or (iii) AVR with other surgery 
(AVR+Other). Here, “other surgery” was defined as any mitral valve procedure, tricuspid 
valve procedure, pulmonary valve procedure, major aortic surgery, or other cardiothoracic 
procedures. 
For both the UK TAVR registry and the NACSA registry, the British Cardiovascular 
Intervention Society and the Society for Cardiothoracic Surgery have made significant efforts 
to maintain data flows during this period, and have provided weekly uploads of data. 
Outcomes 
The primary outcome considered in this study was presentation and treatment of severe 
symptomatic aortic stenosis with either SAVR or TAVR. As secondary outcomes, we 
considered 30-day mortality and post-procedural length of stay. Mortality information was 
provided by linking the UK TAVR registry and the NACSA with the office for national 
statistics civil registration of deaths dataset. Linkage was made based on each patient’s NHS 
number (a unique identifier given to all patients resident in England). Given that death 
registration is mandatory, this mortality data is definitive. We defined post-procedural length 
of stay to be the number of days between the TAVR/SAVR procedure and hospital discharge. 
Statistical Analysis 
We excluded any cases in which the age of the patient at the time of the procedure was under 
18 years. Additionally, we excluded cases where the NHS number was missing (since this 
variable was used for mortality linkage) or with missing procedure urgency (since this is a 
crucial variable in describing activity of TAVR/SAVR). Finally, we removed any duplicate 
cases in either datasets, with duplicates identified using NHS number, age at the time of 
operation, sex, admission date, and date/time of the procedure. 
In all analyses, we stratified by procedure type (i.e. isolated AVR, AVR+CABG, AVR+Other 
or TAVR). Our aim was not to compare procedure types, but rather to explore features of 
each therapy individually. We made no formal comparisons between these procedural types, 
since there are a number of confounding factors surrounding the decision-making between 
TAVR/SAVR (many of which are not captured in the dataset) - that is, due to potential for 
confounding by treatment indication. Thus, all analyses focus on within-procedure-type 
comparisons, rather than between-procedure-type comparisons. 
Cases performed between 1st February and June 2020 were defined into a “during COVID-
19” group, with any case performed in these same months across the preceding years 
(i.e. 2017-2019) being defined into a “pre-COVID-19” group. The 1st February 2020 was 
chosen since the first COVID-19 case reported in England was on 28th January 2020. A 
sensitivity analysis was undertaken, where we took 1st April as the cut-off point (based on 
date of UK lockdown); results were quantitatively similar to those reported here (available on 
request). 
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We report patient baseline characteristics for each procedure type (i.e. isolated AVR, 
AVR+CABG, AVR+Other or TAVR), as whole cohorts and across the “during COVID-19” 
and “pre-COVID-19” groups. Continuous variables were reported using the mean with 
standard deviations. Categorical variables were presented as frequencies of occurrence with 
relative percentages. Temporal changes in predicted procedural risk are displayed by plotting 
the monthly average of the UK TAVR prediction model [22] for all TAVR procedures, and 
the Logistic EuroSCORE [23] for all SAVR procedures through time. These models were 
chosen for their respective uses as benchmarking tools for TAVR and SAVR. For the 
purposes of calculating the risk predictions, missing values in any predictor variables were set 
to “risk factor absent”, representing a plausible missingness process in the registries 
[19,22,24]. 
The number of procedures per month was calculated across the full study period, separately 
for isolated AVR, AVR+CABG, AVR+Other and TAVR. Percentage increase or decrease in 
monthly activity was calculated for each “during COVID-19” month, against the respective 
“pre-COVID-19” months. Similarly, we calculated the minimum, mean and maximum 
number of TAVR/SAVR procedures per month across 2017 and 2019, and compared these 
visually with the corresponding monthly counts in 2020 (up until June 2020). We fitted 
negative binomial models to the number of TAVR/SAVR procedures performed per month 
between January 2017 and December 2019, using time as covariates, which was modelled 
both continuously to capture increasing/decreasing trends in outcome and as a factor variable 
of month to capture any seasonality. This model was used to estimate the expected number of 
TAVR/SAVR procedures per month in 2020, to compare with the observed activity level. 
For each of the four procedural types (i.e. isolated AVR, AVR+CABG, AVR+Other or 
TAVR), we compared mortality up to 30-days, across the “during COVID-19” and “pre-
COVID-19” groups by fitting a Cox proportional hazards model, with the COVID-19 group 
as a covariate. Additionally, we adjusted for procedural risk by including the linear predictor 
of the UK TAVR prediction model [22] or the Logistic EuroSCORE [23], as appropriate. 
Differences in post-procedural length of stay between the “during COVID-19” and “pre-
COVID-19” groups were also investigated by fitting a Cox proportional hazards model, with 
the aforementioned variables as covariates. The proportional hazards assumption was 
checked by examining the Schoenfeld residuals. 
All analyses were performed using R version 4.0.0 [25], along with the tidyverse suite of 
packages [26], and the survival package [27,28]. 
Results 
The UK TAVR registry included 13995 procedures across the study period, of which we 
included 13376 in our analysis after applying the inclusion and exclusion criteria. The 
NACSA registry included 97108 cases over the study period, of which we included 26171 
SAVR procedures, comprised of 12328 (47.1%) isolated AVR, 7829 (29.9%) AVR+CABG, 
and 6014 (23%) AVR+Other cases. 
Table 1 shows the baseline characteristics of the isolated AVR, AVR+CABG, AVR+Other 
and TAVR cases included in this study. The mean age of isolated AVR, AVR+CABG, 
AVR+Other and TAVR was 67.7, 72.3, 62.9 and 81.3, respectively. Across all surgical 
groups, the majority of cases were male. For the surgical AVR groups, the mean Logistic 
EuroSCORE was 7.52%, 10.7% and 13.9% for isolated AVR, AVR+CABG and 
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AVR+Other, respectively, while the mean UK TAVR prediction model was 3.13% ( Table 
1). 
TAVR and SAVR Activity 
There has been a steady increase in the number of TAVR procedures performed per month 
between January 2017 and December 2019, with the majority of procedures being elective ( 
Figure 1). While the number of monthly AVR+CABG and AVR+Other procedures remained 
relatively stable pre-2020, there was a slight decrease in the number of elective isolated AVR 
cases per month in 2019. Specifically, the average number of elective isolated AVR cases per 
month was 250 in 2017 and 252 in 2018, while the monthly activity in 2019 decreased from 
226 cases in January, to 151 cases by December ( Figure 1). This trend continued into early 
2020, with isolated AVR and AVR+CABG activity being lower throughout 2020, compared 
with historic levels ( Figure 2). After 1st March 2020 there was a significant drop in activity 
across all AVR procedures compared with historic levels ( Figure 2). There was a slight 
recovery in AVR activity in May and June 2020. 
The drop in AVR activity was particularly pronounced for elective cases. The number of 
elective SAVR procedures, was below 100 cases per month after March 2020 for each of 
isolated AVR, AVR+CABG and AVR+Other ( Figure 1). In contrast, while the number of 
elective TAVR cases also dropped after March 2020, there remained >100 elective TAVR 
cases per month. The relative drop (percentage change) in monthly activity between 2020 and 
historic levels was lower for TAVR than SAVR with a maximum percentage difference of 
83.5%, 91.8%, 72.6% and 46.3%, for isolated AVR, AVR+CABG, AVR+Other and TAVR, 
respectively ( Figure 2, panel B). 
Fitting a negative binomial model to the monthly TAVR and SAVR procedures between 
2017 and 2019 shows the expected and actual monthly AVR activity during 2020 ( Figure 3). 
Specifically, the estimated difference (95% CI) in the number of TAVR cases per month 
compared with those expected based on historic trends was -41 (-79, -3) in March 2020, -222 
(-257, -187) in April 2020, -188 (-226, -150) in May 2020, and -197 (-234, -159) in June 
2020 ( Figure 3, panel B). The estimated decrease in Isolated AVR activity was -189 (-220, -
158), -233 (-260, -207), -206 (-235, -177) and -171 (-199, -143), across March-June 2020, 
respectively. Similar observations were made for AVR+CABG and AVR+Other cases ( 
Figure 3, panel B). Cumulatively, over the period March to June 2020, this amounts to an 
estimated expected drop of 2294 (95% CI 1872, 2716) cases of severe aortic stenosis in 
England, of which 799 (95% CI 685, 913) were for isolated AVR, 488 (95% CI 407, 570) 
were for AVR+CABG, 358 (95% CI 280, 436) were for AVR+Other, and 648 (95% CI 500, 
796) were for TAVR. 
Evolution of Patient Demographics and Procedural Risk 
Table 2 shows patient baseline characteristics of isolated AVR cases across the pre-COVID-
19 and during-COVID-19 groups. For isolated AVR, the mean age was significantly lower in 
the during-COVID-19 group than the pre-COVID-19 group (p<0.001), and there was a 
significantly higher CCS angina status (p<0.001), NYHA class (p<0.001) and mean PA 
systolic pressure (p<0.001). For AVR+CABG, there was no evidence of a significant 
difference in the majority of patient demographics between the during-COVID-19 group and 
the pre-COVID-19 group (Supplementary Table 1). Specifically, NYHA class (p<0.001) 
and mean PA Systolic pressure (p=0.004) were significantly higher in the during-COVID-19 
group compared to the pre-COVID-19 group. For AVR+Other, there was a significantly 
higher proportion of male patients (p=0.001, Supplementary Table 2), and a higher NYHA 
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class (p=0.029), between the during-COVID-19 group and the pre-COVID-19 group. For 
TAVR cases, the mean age, proportion of current/ex smokers and mean creatinine were 
significantly lower in the during-COVID-19 group compared with the pre-COVID-19 group 
(Table 3). Additionally, there was a lower proportion of TAVR cases with previous MI 
(p<0.001), previous cardiac surgery (p<0.001), and extracardiac arteriopathy (p=0.010) in the 
during-COVID-19 group, compared with the pre-COVID-19 group. The distribution of 
procedure urgency categories was significantly different between the during-COVID-19 
group and the pre-COVID-19 group, for isolated AVR (p<0.001, Table 2), AVR+CABG 
(p=0.001, Supplementary Table 1), AVR+Other (p<0.001, Supplementary Table 2), and 
TAVR (p<0.001, Table 3). 
Overall procedural risk, as estimated by the Logistic EuroSCORE, has remained relatively 
stable over time for isolated AVR, AVR+CABG and AVR+Other (Supplementary Figure 
1). There was no significant difference in the mean Logistic EuroSCORE between the pre-
COVID-19 groups and during-COVID-19 groups for isolated AVR, AVR+CABG or 
AVR+Other cases (Table 2, Supplementary Table 1 and Supplementary Table 2). For 
TAVR, overall procedural risk, as estimated by the UK TAVR prediction model, dropped 
significantly over 2017, with this stabilizing to approximately 4% for non-elective cases and 
approximately 2.5% for elective cases (Supplementary Figure 1). While the mean UK 
TAVR prediction model was significantly lower in the during-COVID-19 group compared 
with the pre-COVID-19 group (p<0.001, Table 3), this was largely driven by 2017 cases 
(Supplementary Figure 1). 
Between 2017 and December 2019, there has been a steady increase in the monthly TAVR 
activity in the lowest quantiles of risk strata (estimated by UK TAVR prediction model), 
while the monthly activity in the highest quantiles of risk strata as remained relatively stable 
(Supplementary Figure 2). After March 2020, TAVR activity was reduced across all 
quantiles of risk strata. In contrast, the monthly activity of isolated AVR, AVR+CABG and 
AVR+Other has been gradually decreasing through time across all quantiles of risk strata 
(defined by Logistic EuroSCORE), with this continuing post March 2020 (Supplementary 
Figure 3, Supplementary Figure 4, and Supplementary Figure 5). 
Outcomes 
The overall (unadjusted) Kaplan-Meier estimates of 30-day survival were 98.5% for isolated 
AVR, 95.9% for AVR+CABG, 94.9%, for AVR+Other, and 97.5% for TAVR. We found no 
significant difference in mortality hazards up to 30-days post procedure between the pre-
COVID-19 group and the during-COVID-19 group for isolated AVR, AVR+CABG, 
AVR+Other or TAVR ( Table 4). 
The median length of stay (LOS) following TAVR was 3 days (interquartile range: 2-5 days) 
in the pre-COVID-19 group, and 2 days (interquartile range: 1-3 days) in the during-COVID-
19 group. The median (interquartile range) LOS in the pre-COVID-19 group for isolated 
AVR, AVR+CABG and AVR+Other was 7 (5-9) days, 8 (6-12) days and 9 (6-15) days, 
respectively, with these being 6 (5-9) days, 7 (5-10) days and 8 (6-13) days in the during-
COVID-19 group. For AVR+CABG and AVR+Other procedures performed in the during-
COVID-19 period, the adjusted hazard ratios (95% CI) for early discharge were 1.21 (1.08, 
1.35)and 1.16 (1.04, 1.3), respectively, showing significantly shorter LOS ( Table 5). For 
TAVR, the hazard ratio for shorter LOS was modelled as a function of time to account for 
non-proportional hazards, with time demonstrating significantly shorter LOS for the during-
COVID-19 group, up to 2 days post procedure. 
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Discussion 
This national study is the first to investigate activity and outcomes following all aortic valve 
replacement procedures in contemporary practice, including the potential indirect impacts of 
the COVID-19 pandemic. We observed a rapid and significant decrease in TAVR and SAVR 
activity during the COVID-19 pandemic. We estimated that over the period March to June 
2020, this decline in activity accounts for an estimated 2294 patients with severe aortic 
stenosis left untreated by TAVR or surgical intervention. This will have major implications 
on this cohort of patients whose untreated mortality is high. Nevertheless, we also report that 
despite restructure of healthcare services nationally during COVID-19, overall procedural 
risk has maintained relatively constant, and there was no evidence of a difference in 
procedure-related mortality outcomes during this period. 
The treatment of severe aortic stenosis has evolved rapidly over the last decade, moving from 
SAVR being the default treatment modality, to a situation in which TAVR is now an 
evidence-based option at all surgical risk categories [14–18]. This study observed changes in 
TAVR and SAVR activity, with steadily increasing TAVR activity and corresponding slight 
decreases in elective isolated AVR cases, up-to 2019. This supports previous findings in this 
area [19]. Although TAVR is currently only approved for inoperable or high-risk cases in the 
UK, the evidence of equivalence in low-risk cases in accumulating [18,29]. This may 
partially explain our finding of a steadily increasing proportion of TAVR cases within the 
lowest quantile of risk (as quantified by the UK TAVR prediction model), prior to 2020. The 
observed decrease in SAVR activity (particularly elective isolated AVR cases) before 
COVID-19, also provides evidence that the clinical envelope for TAVR has expanded into 
lower risk cases within real-world contemporary practice. 
Inevitably, the initiation of national lockdown in the UK was associated with a significant 
reduction in the monthly number of TAVR and SAVR procedures being performed. We 
found a maximum percentage decrease in monthly activity between January and June 2020 
compared with corresponding historic levels of 83.5%, 91.8%, 72.6% and 46.3%, for isolated 
AVR, AVR+CABG, AVR+Other and TAVR, respectively, demonstrating a relatively 
smaller fall in TAVR than SAVR. Even between March and June 2020, there remained over 
100 elective TAVR cases per month, compared with a near-complete reduction in elective 
SAVR. One potential explanation is that TAVR has a very low probability of requiring stay 
in an intensive treatment unit after the procedure, which is important given constraints during 
the COVID-19 pandemic. Indeed, during the pandemic, patients with severe symptomatic 
aortic stenosis were recommended to be treated by TAVR where appropriate [30]. However, 
given that the UK TAVR registry and the NACSA dataset does not contain information on 
the decision-making behind the SAVR or TAVR choice, we are not able to investigate this 
directly within this study. 
The observed reduction in TAVR/SAVR activity was largely driven by elective cases, with 
this study showing that non-elective cases have remained relatively stable post March 2020. 
A possible explanation for this was that the UK government response to the COVID-19 
pandemic was to recommend cancellation of elective procedures [31]. This was made to 
allow a re-structuring of hospital services, thereby allowing more staff and resource to deal 
with the increased admissions due to COVID-19. Simultaneously, this reduces exposure of 
individual patients and their relatives to the hospital environment, and reduces exposure of 
healthcare workers to asymptomatic COVID-19 patients. We observed that monthly activity 
for TAVR and SAVR had a slight recovery in May and June 2020, following the initial drop 
during March and April 2020. We were unable to investigate the reasons for this, but a 
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similar observation was made for admissions for acute coronary syndrome [6]. Again, one 
could speculate that this relates to decreasing demands on healthcare systems as the pandemic 
evolved, with an aim to resume elective activity once the peak of the pandemic had passed. 
While the observed temporal changes in TAVR and SAVR activity are perhaps unsurprising, 
the marked drop in cases post COVID-19 does raise important implications for healthcare 
resource planning in the near-to-medium term. Our estimates surrounding the difference in 
the number of AVR procedures per month in 2020 compared with historic trends mean that 
there will likely be significant increased demand for TAVR and SAVR. This will lead to an 
inevitable increase in waiting times [32], and associated adverse impacts on outcomes [33]. 
Recommendations for how to manage this challenge are emerging [32,34]. Since the NACSA 
and UK TAVR registry datasets only contain data on those who undergo TAVR/SAVR, it 
was not possible for us to forecast future demand for AVR (since we do not have information 
on patients who are candidates for AVR, but who have not currently undergone the 
procedure). However, based on the available data, we estimated that, cumulatively, between 
March and June 2020, there were 2294 (95% CI 1872, 2716) cases of severe aortic stenosis 
who have not received treatment in England. Previous studies have shown that, under normal 
circumstances, the median wait-time for TAVR is 80 days [35]. Thus, assuming these figures 
apply to AVR generally, one could postulate that this means approximately 1147 patients will 
remain untreated by 80 days (increasing to 1720 if procedures in the near-to-medium term are 
made at 50% capacity), even without considering the additional cases over this period. While 
such figures are an approximation, they do give some indication of expected levels of 
increased demand that SAVR and TAVR centres might expect as the lockdown restriction 
continues to be relaxed. On a national-level, it is clear that strategies will be required to 
mitigate this large backlog of cases, in order to reduce avoidable deaths in patients with 
severe symptomatic aortic stenosis who remain untreated. 
Indeed, it remains unclear what effect the reduction in the number of procedures per month 
has had on outcomes for patients with aortic stenosis who would otherwise have been treated 
with AVR during March - June 2020. Some of these patients might be alive and waiting for 
AVR intervention, or might have died from aortic stenosis, COVID-19 or from other causes. 
Previous studies have estimated that the risk of death whilst waiting for intervention for 
server aortic stenosis in routine clinical practice is between 2% and 14% [36]. This means 
that of the estimated 2294 currently delayed cases, there will be between 46 and 321 deaths 
while waiting for intervention, if capacity returns to normal. Any additional delays due to the 
backlog will lead to increased mortality. Of course, these are approximate figures and does 
not account for excess mortality due to COVID-19 [37]. 
Several limitations should be noted when interpreting the results of this study. Firstly, we 
make no statistical comparisons between isolated AVR, AVR+CABG, AVR+Other or TAVR 
groups. Any such comparisons would be subject to confounding by indication. This means 
that we were not able to investigate changes in patient-level propensity to undergo SAVR 
vs. TAVR through the COVID-19 period, since the decision-making behind the SAVR 
vs. TAVR choice was not recorded in these data. Secondly, while we used the Logistic 
EuroSCORE to summarise overall SAVR procedural risk, this model is known to overpredict 
mortality risk. However, this model is commonly used for benchmarking in national 
cardiovascular registries, and we use the model in the same capacity here. Thirdly, this 
analysis is limited to procedures in England; however, given that COVID-19 has caused 
changes in healthcare utilisation globally, one might expect similar findings in other 
healthcare settings. Finally, some delays in reporting during the pandemic might contribute to 
some of the results; however, the British Cardiovascular Intervention Society and the Society 
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for Cardiothoracic Surgery have made significant efforts to maintain data flows during this 
period, and have provided weekly uploads of data. Thus, this limitation is potentially 
minimised. 
In conclusion, this study has demonstrated a significant drop in TAVR and SAVR activity 
following the COVID-19 outbreak in the UK. The case-mix of patients who have undergone 
SAVR or TAVR during the COVID-19 period was similar to the case-mix seen in the pre-
COVID-19 period, with no evidence of a difference in mortality outcomes. The activity 
across both SAVR and TAVR should be closely monitored to ensure that monthly cases 
correctly return to expected levels. These data suggest that there will be a sharp rise in 
demand for AVR intervention in the near-to-medium term, with the potential for an upturn in 
mortality in patients waiting to be treated. 
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Tables 
Table 1: Baseline characteristics of the SAVR and TAVR cases included in this analysis. 
TAVR: Transcatheter Aortic Valve Replacement; SAVR: Surgical Aortic Valve Replacement. 
Note: the numbers in some categories might not sum to the total due to missing data. 
 Isolated 
AVR AVR+CABG AVR+Other TAVR 
n 12328 7829 6014 13376 
Age, years (mean (SD)) 67.74 
(11.66) 




Female (%) 4713 
(38.2) 
1766 (22.6) 2030 (33.8) 5971 
(44.7) 
CCS Angina status (%)     
     No angina 7056 
(57.4) 
2336 (30.0) 3999 (66.7) 9467 
(75.7) 
     Class I 1497 
(12.2) 
811 (10.4) 657 (11.0) 893 ( 7.1) 
     Class II 2606 
(21.2) 
2745 (35.2) 847 (14.1) 1493 
(11.9) 
     Class III or IV 1124 ( 9.2) 1904 (24.4) 496 ( 8.3) 647 ( 5.2) 
NYHA (%)     
     Class I 1275 
(10.5) 
795 (10.3) 940 (15.9) 860 ( 7.0) 
     Class II 4854 
(39.8) 
3203 (41.5) 2052 (34.8) 2851 
(23.0) 
     Class III or IV 6058 
(49.7) 
3714 (48.2) 2910 (49.3) 8658 
(70.0) 
Previous MI (%) 721 ( 5.9) 1995 (25.6) 290 ( 4.9) 1916 
(15.1) 
Previous PCI (%) 623 ( 5.1) 911 (11.8) 213 ( 3.6) 2153 
(17.0) 
Previous Cardiac Surgery (%) 846 ( 7.4) 198 ( 2.7) 848 (15.3) 2150 
(17.8) 
Diabetic (%) 2323 
(18.9) 
2265 (29.0) 717 (11.9) 3057 
(24.2) 
Current/Ex Smoker (%) 6469 
(52.9) 
4805 (61.8) 2991 (50.1) 5819 
(50.6) 
Creatinine, umol/L (mean (SD)) 89.51 
(45.54) 




History of neurological disease (%) 1059 ( 8.6) 787 (10.1) 592 ( 9.9) 1992 
(15.6) 
Extracardiac Arteriopathy (%) 623 ( 5.1) 1020 (13.0) 438 ( 7.3) 1678 
(13.4) 
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Atrial Fibrillation or Flutter (%) 1109 ( 9.1) 1056 (13.5) 1405 (23.6) 3385 
(28.4) 
One or more vessel with >50% 
diameter stenosis (%) 
562 ( 5.1) 6870 (96.9) 236 ( 5.0) 3659 
(32.1) 
PA Systolic (mean (SD)) 27.55 
(20.07) 




LV Function (%)     
     Good (LVEF > 50%) 9739 
(79.7) 
5512 (70.9) 4239 (71.1) 8913 
(72.3) 
     Moderate (LVEF 31 - 50%) 1918 
(15.7) 
1792 (23.1) 1375 (23.1) 2281 
(18.5) 
     Poor (LVEF < 30%) 567 ( 4.6) 467 ( 6.0) 345 ( 5.8) 1132 ( 9.2) 
Height, m (mean (SD)) 1.68 (0.10) 1.70 (0.10) 1.71 (0.11) 1.65 (0.10) 
Weight, kg (mean (SD)) 82.73 
(18.24) 




Non-Elective (%) 2769 
(22.5) 
2472 (31.6) 2022 (33.6) 2590 
(19.4) 
Logistic EuroSCORE (mean (SD)) 7.52 (8.47) 10.67 (11.07) 13.93 
(14.39) 
NaN (NA) 
UK TAVR CPM (mean (SD)) NaN (NA) NaN (NA) NaN (NA) 3.13 (2.43) 
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Table 2: Baseline characteristics of the Isolated AVR cases included in the pre-COVID-19 
and during-COVID-19 groups, as defined in the methods section. AVR: Aortic Valve 
Replacement. Note: this only included cases in Febuary-June each year, and the numbers in 





n 4806 694  
Age, years (mean (SD)) 67.87 (11.60) 65.85 (10.84) <0.001 
Female (%) 1875 (39.0) 249 (35.9) 0.123 
CCS Angina status (%)   <0.001 
     No angina 2788 (58.3) 372 (53.8)  
     Class I 558 (11.7) 86 (12.4)  
     Class II 1013 (21.2) 138 (20.0)  
     Class III or IV 422 ( 8.8) 95 (13.7)  
NYHA (%)   <0.001 
     Class I 481 (10.1) 48 ( 7.1)  
     Class II 1895 (39.9) 230 (33.8)  
     Class III or IV 2377 (50.0) 402 (59.1)  
Previous MI (%) 275 ( 5.7) 32 ( 4.6) 0.269 
Previous PCI (%) 214 ( 4.5) 39 ( 5.6) 0.227 
Previous Cardiac Surgery (%) 347 ( 7.8) 46 ( 7.2) 0.620 
Diabetic (%) 931 (19.5) 142 (20.5) 0.567 
Current/Ex-Smoker (%) 2521 (52.9) 370 (53.9) 0.666 
Creatinine, umol/L (mean (SD)) 89.36 (43.83) 87.29 (42.29) 0.254 
History of neurological disease (%) 390 ( 8.2) 60 ( 8.7) 0.666 
Extracardiac Arteriopathy (%) 242 ( 5.0) 29 ( 4.2) 0.379 
Atrial Fibrillation or Flutter (%) 449 ( 9.4) 49 ( 7.1) 0.060 
One or more vessel with >50% diameter 
stenosis (%) 
223 ( 5.2) 35 ( 5.7) 0.732 
PA Systolic (mean (SD)) 26.00 (19.88) 36.57 (31.66) <0.001 
LV Function (%)   0.456 
     Good (LVEF > 50%) 3778 (79.4) 534 (77.4)  
     Moderate (LVEF 31 - 50%) 758 (15.9) 119 (17.2)  
     Poor (LVEF < 30%) 222 ( 4.7) 37 ( 5.4)  
Height, m (mean (SD)) 1.68 (0.10) 1.69 (0.11) 0.041 
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Weight, kg (mean (SD)) 82.77 (18.18) 84.56 (18.97) 0.016 
Non-Elective (%) 1074 (22.3) 225 (32.4) <0.001 
Logistic EuroSCORE (mean (SD)) 7.48 (8.23) 6.90 (8.17) 0.080 
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Table 3: Baseline characteristics of the TAVR cases included in pre-COVID-19 and during-
COVID-19 groups, as defined in the methods section. TAVR: Transcatheter Aortic Valve 
Replacement. Note: this only included cases in Febuary-June each year, and the numbers in 





n 4743 1390  
Age, years (mean (SD)) 81.36 (7.36) 80.65 (7.12) 0.001 
Female (%) 2164 (45.7) 615 (44.2) 0.363 
CCS Angina status (%)   0.071 
     No angina 3376 (75.1) 981 (78.0)  
     Class I 344 ( 7.6) 72 ( 5.7)  
     Class II 537 (11.9) 146 (11.6)  
     Class III or IV 240 ( 5.3) 59 ( 4.7)  
NYHA (%)   0.072 
     Class I 306 ( 6.9) 84 ( 6.7)  
     Class II 1015 (22.7) 250 (19.8)  
     Class III or IV 3141 (70.4) 928 (73.5)  
Previous MI (%) 746 (16.3) 146 (11.4) <0.001 
Previous PCI (%) 770 (17.0) 190 (14.8) 0.066 
Previous Cardiac Surgery (%) 826 (19.0) 178 (13.9) <0.001 
Diabetic (%) 1090 (23.9) 312 (24.4) 0.756 
Current/Ex-Smoker (%) 2058 (48.9) 508 (45.4) 0.041 
Creatinine, umol/L (mean (SD)) 105.73 
(66.89) 
101.14 (56.44) 0.029 
History of neurological disease (%) 718 (15.6) 205 (15.9) 0.786 
Extracardiac Arteriopathy (%) 641 (14.2) 143 (11.3) 0.010 
Atrial Fibrillation or Flutter (%) 1253 (28.9) 353 (28.3) 0.705 
One or more vessel with >50% diameter 
stenosis (%) 
1313 (31.6) 332 (29.2) 0.131 
PA Systolic (mean (SD)) 38.22 (15.02) 37.12 (15.60) 0.139 
LV Function (%)   0.162 
     Good (LVEF > 50%) 3224 (72.4) 877 (71.9)  
     Moderate (LVEF 31 - 50%) 836 (18.8) 214 (17.6)  
     Poor (LVEF < 30%) 394 ( 8.8) 128 (10.5)  
Height, m (mean (SD)) 1.65 (0.10) 1.66 (0.10) 0.055 
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Weight, kg (mean (SD)) 75.66 (17.37) 76.51 (17.47) 0.126 
Non-Elective (%) 832 (17.5) 403 (29.0) <0.001 
UK TAVR CPM (mean (SD)) 3.23 (2.76) 2.89 (1.80) <0.001 
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Table 4: Multivariable adjusted mortality hazard ratios (95% confidence interval) of 
COVID-19 period (during- vs. pre-) for up-to 30-day mortality. All values are adjusted for 
overall procedural risk (Logistic EuroSCORE for SAVR and UK TAVR prediction model for 
TAVR cases). TAVR: Transcatheter Aortic Valve Replacement; SAVR: Surgical Aortic Valve 
Replacement. 
Surgical Group Hazard Ratio (95% CI) p-value 
Isolated AVR 1.15 (0.63, 2.12) 0.643 
AVR+CABG 1.19 (0.77, 1.83) 0.431 
AVR+Other 1.01 (0.63, 1.61) 0.983 
TAVR 0.7 (0.45, 1.07) 0.098 
 
Table 5: Multivariable adjusted hazard ratios (95% confidence interval) for discharge across 
COVID-19 period (during- vs. pre-). The event is discharge, so a hazard ratio greater than 
one implies shorter length of stay. All values are adjusted for overall procedural risk 
(Logistic EuroSCORE for SAVR and UK TAVR prediction model for TAVR cases). TAVR: 
Transcatheter Aortic Valve Replacement; SAVR: Surgical Aortic Valve Replacement. 
Surgical Group (period, where applicable) Hazard Ratio (95% CI) p-value 
Isolated AVR 1.02 (0.94, 1.11) 0.565 
AVR+CABG 1.21 (1.08, 1.35) p<0.001 
AVR+Other 1.16 (1.04, 1.3) 0.006 
TAVR   
     0-1 Days 2.87 (2.54, 3.24) p<0.001 
     1-2 Days 1.51 (1.34, 1.69) p<0.001 
     2+ Days 1.07 (0.95, 1.21) 0.247 
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Figures Legend 
 
Figure 1: Temporal plot of the number of TAVR and SAVR procedures per month, stratified 
according to procedure urgency. The vertical dotted line denotes 23rd March 2020 (date of 
UK lockdown) with 1st March denoted by the vertical dashed line. TAVR: Transcatheter 
Aortic Valve Replacement; SAVR: Surgical Aortic Valve Replacement. 
 
Figure 2: Panel A: Temporal plot of the number of TAVR and SAVR procedures per month 
during 2020, compared with monthly averages (minimum and maximum shown by shaded 
region) across all other years in the dataset. Panel B: Percentage change between the mean 
monthly activity in 2017-2019 and the monthly activity in 2020; negative percentage change 
denotes increase in 2020 over historic levels. TAVR: Transcatheter Aortic Valve 
Replacement; SAVR: Surgical Aortic Valve Replacement. 
 
Figure 3: Panel A: Temporal plot of the observed and expected number of TAVR/SAVR 
procedures per month. Panel B: The difference between the observed and expected number of 
TAVR/SAVR procedures per month. In both plots the expected monthly count is estimated 
from a negative binomial model fitted to the 2017-2019 data. The vertical dotted line denotes 
23rd March 2020 (date of UK lockdown) with 1st March denoted by the vertical dashed line. 
TAVR: Transcatheter Aortic Valve Replacement; SAVR: Surgical Aortic Valve Replacement. 
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